Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2013

  Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2013

      Adoption of all resolutions submitted to the vote of Shareholders.

Business Wire

PARIS -- May 31, 2013

Regulatory News :

The Combined Shareholders’ Meeting of Ipsen S.A. (Paris:IPN) (Euronext: IPN;
ADR: IPSEY), chaired by Marc de Garidel, Chairman and Chief Executive Officer,
was held today, in the presence of the members of the Board of Directors and
the Group General Management.

The Shareholders’ Meeting approved all the resolutions submitted by the Board
of Directors and in particular the distribution of €0.80 dividend per share to
be paid on 10 June 2013 (ex-dividend date 5 June 2013) and the renewal of the
terms of office as Directors of Mr Antoine Flochel and Mr Gérard Hauser as
well as the appointment of Mrs Martha Crawford as Director.

During the Meeting, Marc de Garidel, Christel Bories, Deputy Chief Executive
Officer and Susheel Surpal, Executive Vice President, Chief Financial Officer,
presented, in particular, the major events and financial results for 2012 as
well as the 2013 outlook and 2013 first quarter sales.

About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by 3 franchises: neurology / Dysport^®,
endocrinology / Somatuline^® and uro-oncology / Decapeptyl^®. Moreover, the
Group has an active policy of partnerships. Ipsen's R&D is focused on its
innovative and differentiated technological platforms, peptides and toxins. In
2012, R&D expenditure totaled close to €250 million, representing more than
20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s
shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code:
FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The
Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I
American Depositary Receipt (ADR) program, which trade on the over-the-counter
market in the United States under the symbol IPSEY. For more information on
Ipsen, visit www.ipsen.com.

Contact:

Media
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Email: didier.veron@ipsen.com
or
Financial Community
Pierre Kemula
Vice President Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
Email: pierre.kemula@ipsen.com
or
Brigitte Le Guennec
Media and Public Relations Officer
Tel. : +33 (0)1 58 33 51 17
Fax : 01 58 33 50 58
Email :  brigitte.le.guennec@ipsen.com
or
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
Email: stephane.durant.des.aulnois@ipsen.com
 
Press spacebar to pause and continue. Press esc to stop.